Renal Disease Therapeutics Market

Global Renal Disease Therapeutics Market Size (2024 to 2029)

The global renal disease therapeutics market size is predicted to grow at an impressive CAGR between 2024 to 2029.

Renal diseases are progressive loss of the proper functioning of the kidneys. Over a more extended period, the associated renal system fuels the market because of its high incidence rate worldwide. The kidneys have many life-sustaining functions, such as cleansing the blood by filtering waste products and excess fluid, regulating blood pressure, and maintaining the balance of salt and minerals. When kidney failure occurs, they ultimately lose their vital function, which is fatal. Kidney damage/failure can be developed acutely (AKI) and over time (CKD). Three types of treatment are most prevalent to cure kidney failure prescription medications, surgical intervention, and dialysis (peritoneal dialysis, hemodialysis, and continuous renal replacement therapy), which are frequently used in combination to treat a single case of renal failure.

MARKET DRIVERS

Some of the key drivers of the renal disease therapeutics market are the increasing aging population, growing awareness of both acute and chronic kidney disease, an increasing number of individuals with insurance due to the Affordable Care Act, an Increasing Diabetic Population, and rising demand for advanced diagnostics and therapeutics for the disease.

MARKET RESTRAINTS

Disparities of Renal Transplant Therapy, the expiration of patents of some of the branded drugs for late-stage CKD, and changing reimbursement scenarios in some significant countries, Negative Societal Effects, are the restraints that hinder the growth of the market.

REPORT COVERAGE

REGIONAL ANALYSIS

Geographically, the North American market is predicted to dominate the global renal disease therapeutics market during the forecast period. Europe comes next. However, the Asia-Pacific is projected to show the highest CAGR over the forecast period due to an increasing number of high blood pressure and diabetic patients and a growing demand for advanced diagnostics and therapeutics in the region.

KEY PLAYERS IN THE RENAL DISEASE THERAPEUTICS MARKET

Companies leading the global renal disease therapeutics market profiled in the report are Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Inc., Shire Inc., Fresenius Medical Care, Baxter International, and Davita Healthcare Partners.

DETAILED SEGMENTATION OF THE GLOBAL RENAL DISEASE THERAPEUTICS MARKET

This research report on the global renal disease therapeutics market has been segmented and sub-segmented based on application mode, treatment, and region.

By Application Mode

• Kidney Stone Disease
• End-Stage Kidney Disease
• Kidney Failure
• Chronic Kidney Disease
• Hypertension
• Diabetes
• Anemia

By Treatment

• Dialysis Equipment
• Renal Denervation Devices
• Wearable Artificial Kidney Device
• Distal Embolic Protection Devices

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa